The Valley Desk

Conference abstractO6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trialPublished

O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial

13 of 92 authors shown in byline order.

Read the publication ↗

Regional connection

Verified An author affiliation on the Crossref record names Jefferson Einstein Philadelphia Hospital, with Jefferson Health linked by the institution reference. Affiliation source

Publication record

Type
Conference abstract
Venue
O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial
Published
Added to directory
Source checked

Report a correction or request removal